GlassScriptPhysician profile
Michael B Stotler
NPI 1578613014
$250,023.89
in general payments reported to CMS, 2019-2025
24 companies · $32K in 2025
The $32K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $37K · 2021: $20K · 2022: $20K · 2023: $31K · 2024: $37K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Honoraria: $21K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $5,336 · Food and Beverage: $4,407 · Education: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,687.50 |
| Honoraria | $20,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,247.50 |
| Travel and Lodging | $5,336.22 |
| Food and Beverage | $4,407.30 |
| Education | $261.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $90,322.28 | 2019-2021 | |
| Axsome Therapeutics, INC. | $79,949.26 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $37,788.66 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $18,532.82 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $9,589.91 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $9,109.94 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $1,715.43 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $974.81 | 2019-2025 | Austedo Xr, Austedo |
| Corium, LLC | $446.37 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $360.05 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $324.40 | 2019-2023 | Abilify Maintena |
| Lundbeck LLC | $300.40 | 2019-2020 | |
| Alkermes, INC. | $165.02 | 2019-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $137.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.49 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $62.11 | 2019 | |
| Bausch Health US, LLC | $42.09 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $33.88 | 2019 | |
| Ironshore Pharmaceuticals INC. | $24.73 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $14.77 | 2019 | |
| Neos Therapeutics, LP | $13.24 | 2019 | |
| Merck Sharp & Dohme LLC | $12.01 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.92 | 2022 | |
| Vertical Pharmaceuticals, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stotler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.